Arnhem, The Netherlands, 7 February 2011 — In the February 2011 issue of European Urology, Jean-Nicolas Cornu and colleagues reported the evaluation of the efficacy of prostate cancer (PCa) detection by trained dogs on human urine samples.
In their article, the researchers affirm that volatiles organic compounds (VOCs) in urine have been proposed as cancer biomarkers. In the study, a Belgian Malinois shepherd was trained by the clicker training method (operant conditioning) to scent and recognize urine of people having PCa. All urine samples were frozen for preservation and heated to the same temperature for all tests. After a learning phase and a training period of 24 months, the dog’s ability to discriminate PCa and control urine was tested in a double-blind procedure.
Urine was obtained from 66 patients referred to an urologist for elevated prostate-specific antigen or abnormal digital rectal examination. All patients underwent prostate biopsy and two groups were considered: 33 patients with cancer and 33 controls presenting negative biopsies. The dog completed all the runs and correctly designated the cancer samples in 30 of 33 cases. Of the three cases wrongly classified as cancer, one patient was re-biopsied and a PCa was diagnosed. The sensitivity and specificity were both 91%.
This study shows that dogs can be trained to detect PCa by smelling urine with a significant success rate. It also suggests that PCa gives an odor signature to urine. Identification of the VOCs involved could lead to a potentially useful screening tool for PCa.
The article “Olfactory Detection of Prostate Cancer by Dogs Sniffing Urine: A Step Forward in Early Diagnosis,” by Jean-Nicolas Cornu, Géraldine Cancel-Tassin, Valérie Ondet, Caroline Girardet, Olivier Cussenot is published in European Urology, Volume 59, issue 2, pages 183-316, February 2011, DOI: 10.1016/j.eururo.2010.10.006.
Notes to Editors:
Copies for members of the media are available by contacting the Elsevier press office, email@example.com
About the European Association of Urology (EAU)
The European Association of Urology (EAU) represents more than 16,000 urology professionals across Europe and worldwide. Its mission is to raise the level of urological care in Europe. The EAU has special sections on the Internet, such as Uroweb (www.uroweb.org) and Urosource (www.urosource.com), which allows for direct communication.
European Urology, produced by the EAU, has been a respected urological forum for over 20 years, and is currently read by more than 9,000 urologists across the globe. With an impact factor of 7.667, the journal has become the leading scientific publication in the field of urology.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).